Copyright St. Paul Pioneer Press
To place an obituary, please include the information from the obituary checklist below in an email to obits@pioneerpress.com. There is no option to place them through our website at this time. Feel free to contact our obituary desk at 651-228-5263 with any questions. General Information: Your full name, Address (City, State, Zip Code), Phone number, And an alternate phone number (if any) Obituary Specification: Name of Deceased, Obituary Text, A photo in a JPEG or PDF file is preferable, TIF and other files are accepted, we will contact you if there are any issues with the photo. Ad Run dates There is a discount for running more than one day, but this must be scheduled on the first run date to apply. If a photo is used, it must be used for both days for the discount to apply, contact us for more information. Policies: Verification of Death: In order to publish obituaries a name and phone number of funeral home/cremation society is required. We must contact the funeral home/cremation society handling the arrangements during their business hours to verify the death. If the body of the deceased has been donated to the University of Minnesota Anatomy Bequest Program, or a similar program, their phone number is required for verification. Please allow enough time to contact them especially during their limited weekend hours. A death certificate is also acceptable for this purpose but only one of these two options are necessary. Guestbook and Outside Websites: We are not allowed to reference other media sources with a guestbook or an obituary placed elsewhere when placing an obituary in print and online. We may place a website for a funeral home or a family email for contact instead; contact us with any questions regarding this matter. Obituary Process: Once your submission is completed, we will fax or email a proof for review prior to publication in the newspaper. This proof includes price and days the notice is scheduled to appear. Please review the proof carefully. We must be notified of errors or changes before the notice appears in the Pioneer Press based on each day’s deadlines. After publication, we will not be responsible for errors that may occur after final proofing. Online: Changes to an online obituary can be handled through the obituary desk. Call us with further questions. Payment Procedure: Pre-payment is required for all obituary notices prior to publication by the deadline specified below in our deadline schedule. Please call 651-228-5263 with your payment information after you have received the proof and approved its contents. Credit Card: Payment accepted by phone only due to PCI (Payment Card Industry) regulations EFT: Check by phone. Please provide your routing number and account number. Rates: The minimum charge is $162 for the first 12 lines. Every line after the first 12 is $12. If the ad is under 12 lines it will be charged the minimum rate of $162. Obituaries including more than 40 lines will receive a 7.5% discount per line. On a second run date, receive a 20% discount off both the first and second placement. Place three obituaries and the third placement will be free of charge. Each photo published is $125 per day. For example: 2 photos in the paper on 2 days would be 4 photo charges at $500. Deadlines: Please follow deadline times to ensure your obituary is published on the day requested. Hours Deadline (no exceptions) Ad Photos MEMORIAM (NON-OBITUARY) REQUEST Unlike an obituary, Memoriam submissions are remembrances of a loved one who has passed. The rates for a memoriam differ from obituaries. Please call or email us for more memoriam information Please call 651-228-5280 for more information. HOURS: Monday – Friday 8:00AM – 5:00PM (CLOSED WEEKENDS and HOLIDAYS) Please submit your memoriam ad to memoriams@pioneerpress.com or call 651-228-5280. By MICHELLE CHAPMAN, Associated Press Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about 54% of the combined company. Kenvue shareholders will own about 46% in what is one of the largest corporate takeovers this year. The combined company will have a huge stable of household brands under one roof, putting Kenvue’s Listerine mouthwash and Band-Aid side-by-side with Kimberly-Clark’s Cottonelle toilet paper, Huggies and Kleenex tissues. It will also generate about $32 billion in annual revenue. Kenvue has spent a relatively brief period as an independent company, having been spun off by Johnson & Johnson two years ago. J&J first announced in late 2021 that it was splitting its slow-growth consumer health division from the pharmaceutical and medical device divisions. Kenvue has since been targeted by activist investors unhappy about the trajectory of the company and Wall Street appeared to anticipate some heavy lifting ahead for Kimberly-Clark. Shares of Kimberly-Clark, based in just outside of Dallas, slumped 13% Monday. Kenvue’s stock jumped more than 15%. Kenvue and Tylenol have been thrust into the national spotlight this year as President Donald Trump and Health Secretary Robert F. Kennedy Jr. promoted unproven and in some cases discredited ties between Tylenol, vaccines and the complex brain disorder autism. Trump then urged pregnant women against using the medicine. That went beyond Food and Drug Administration advice that doctors “should consider minimizing” the painkiller acetaminophen’s use in pregnancy — amid inconclusive evidence about whether too much could be linked to autism. Kennedy reiterated the FDA guidance during a press conference last week. He said that there isn’t sufficient evidence to link the drug to autism. “We have asked physicians to minimize the use to when its absolutely necessary,” he said. Kenvue has continued to push back on the Trump administration’s dialogue. “Nothing is more important to us than the health and safety of the people who use our products,” Kenvue said in a statement on its website. “We believe independent, sound science clearly shows that taking acetaminophen does not cause autism. We strongly disagree with allegations that it does and are deeply concerned about the health risks and confusion this poses for expecting mothers and parents.” In July Kenvue, announced that CEO Thibaut Mongon was leaving in the midst of a strategic review with the company under mounting pressure from activist investors. Kimberly-Clark Chairman and CEO Mike Hsu will be chairman and CEO of the combined company. Three members of the Kenvue’s board will join Kimberly-Clark’s board at closing. The combined company will keep Kimberly-Clark’s headquarters in Irving, Texas, but there will be significant operations around Kenvue facilities and locations as well. The deal is expected to close in the second half of next year. It still needs approval from shareholders of both both companies. Kenvue shareholders will receive $3.50 per share in cash and 0.14625 Kimberly-Clark shares for each Kenvue share held at closing. That amounts to $21.01 per share, based on the closing price of Kimberly-Clark shares on Friday. Kimberly-Clark and Kenvue said that they identified about $1.9 billion in cost savings that are expected in the first three years after the transaction’s closing. AP Health Writer Tom Murphy contributed to this report.
